Skip to main content
Clinical Trials/NCT01760720
NCT01760720
Completed
Not Applicable

Methadone Maintenance Treatment (MMT) Care for HIV Prevention: A Randomized Controlled Trial (MMT2)

University of California, Los Angeles1 site in 1 country2,866 target enrollmentMarch 2012
ConditionsStigma

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Stigma
Sponsor
University of California, Los Angeles
Enrollment
2866
Locations
1
Primary Endpoint
Client treatment retention
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

Based on our previous success with the intervention pilot (R34MH083512), we conducted this randomized controlled trial (MMT CARE), which will integrate behavioral intervention components with a primarily pharmacological model of MMT. The intervention focuses on treatment adherence and effective outcomes by reducing stigmatizing attitudes and behaviors among service providers, enhancing their communication skills, and improving their interactions with and support of their clients' behavior changes. Our goal is to bring a contextual change to support a protective environment for clients' motivation and capacity in order to reduce their HIV risk. The findings could benefit not only China but also the global community by effectively combining interventions for controlling the HIV epidemic.

Detailed Description

Injecting drug use is the major mode of HIV transmission for 740,000 people living with HIV (PLH) in China. In response to this situation, China introduced methadone maintenance treatment (MMT) in 2004, which is now dispensed by 701 clinics serving 295,000 clients. Despite this impressive scale-up, China's MMT programs still face serious challenges, including high drop-out rates, a large number of clients who continue to use heroin during MMT, a gap between clients' needs and services availability, providers' lack of skills in counseling and education, and stigma linked to resistance to harm reduction. This study aims to address these challenges. Based on our previous success with the intervention pilot (R34MH083512), we conducted this randomized controlled trial (MMT CARE), which will integrate behavioral intervention components with a primarily pharmacological model of MMT. The intervention focuses on treatment adherence and effective outcomes by reducing stigmatizing attitudes and behaviors among service providers, enhancing their communication skills, and improving their interactions with and support of their clients' behavior changes. Our goal is to bring a contextual change to support a protective environment for clients' motivation and capacity in order to reduce their HIV risk. The findings could benefit not only China but also the global community by effectively combining interventions for controlling the HIV epidemic. The study will be implemented in Sichuan, Guangdong, Hunan, Shaanxi and Jiangsu provinces. A total of 68 MMT clinics will be randomly selected from the five provinces and randomized to either the intervention condition (MMT CARE group) or the control condition. From each selected clinic, we will recruit 6 service providers and 36 clients, totaling 408 service providers and 2,448 clients (204 service provider and 1,224 clients in each condition, respectively). The Specific Aims of the study are as follows: 1. To examine whether providers in the intervention group, compared to providers in the control group, demonstrate improved adherence to MMT protocols, decreased prejudicial attitudes, increased interactions with clients, and increased communications with clients on risk reduction. 2. To examine whether MMT clients in the intervention group, compared to clients in the control group, demonstrate improved treatment adherence/retention, decreased concurrent drug use, increased motivation for behavior change, improved mental health, increased positive support, and reduced HIV risk behaviors. 3. To explore whether providers' improved outcomes are associated with improved client outcomes.

Registry
clinicaltrials.gov
Start Date
March 2012
End Date
December 2015
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Li Li, PhD

Professor in Residence

University of California, Los Angeles

Eligibility Criteria

Inclusion Criteria

  • MMT clients
  • Age 20 and above
  • Currently enrolled in MMT at the participating clinics
  • Informed consent Service providers
  • Age 18 and above
  • Currently working in the participating MMT clinics
  • Informed consent

Exclusion Criteria

  • MMT Clients
  • Psychosis, neurological damage, as judged by an interviewer in consultation with a clinical supervisor
  • Currently under criminal or civil charges
  • Inability to give informed consent
  • Anyone who does not meet the inclusion criteria
  • Service Providers
  • Inability to give informed consent
  • Anyone who does not meet the inclusion criteria.

Outcomes

Primary Outcomes

Client treatment retention

Time Frame: Change from baseline to 6-, 12-, 18- and 24-month follow up

MMT retention will be measured by the treatment status (in treatment vs. drop out) at each follow-up point.

Secondary Outcomes

  • Client's mental health(Change from baseline to 6-, 12-, 18- and 24-month follow up)
  • Provider attitudes toward and interaction with clients(Change from baseline to 6-, 12-, 18- and 24-month follow up)

Study Sites (1)

Loading locations...

Similar Trials